Clinical Application of Nutrition Support Package Before Hepatectomy

NCT ID: NCT04218253

Last Updated: 2020-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective:To confirm the effect of preoperative oral nutrition therapy on patients with malnourished before liver cancer resection.

Study design:Prospective, randomized, controlled clinical study. Primary end point: incidence of all complications 30 days after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Neoplasms Nutrition Therapy Hepatectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nutritional intervention

300 or 500 calories nutritional support before operation according to the level of malnutrition

Group Type EXPERIMENTAL

300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber

Intervention Type DIETARY_SUPPLEMENT

300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).

Dietary mission

Intervention Type BEHAVIORAL

Dietary education was conducted according to preoperative nutritional requirements

control group

Dietary education was conducted according to preoperative nutritional requirements

Group Type OTHER

Dietary mission

Intervention Type BEHAVIORAL

Dietary education was conducted according to preoperative nutritional requirements

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber

300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).

Intervention Type DIETARY_SUPPLEMENT

Dietary mission

Dietary education was conducted according to preoperative nutritional requirements

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Clinical diagnosis of primary liver cancer (including hepatocellular carcinoma, bile duct carcinoma, and mixed cell carcinoma)
* 2\. No contraindications for surgery
* 3\. Eastern Cooperative Oncology Group (ECOG) score of preoperative physical state \<2 points
* 4\. Preoperative liver function score Child-Pugh ≤ 6 points: total bilirubin ≤ 3.0 mg / dl, albumin ≥ 28 g / L, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal
* 5\. Voluntarily enter the study and sign the informed consent form, and communicate well with the researcher

Exclusion Criteria

* 1\. Patients who took fish oil supplements within 3 weeks before the study began
* 2\. Patients with severe nutritional risk: serious nutritional risk should be considered when combining any of the following conditions: weight loss \> 10% within 6 months; digital pain score (NRS) score \> 5 points; BMI \<18.5 kg/m2 (all patients with severe nutritional risk undergo individualized supportive care);
* 3\. Patients with malignant tumors in other parts
* 4\. Patients who are pregnant or lactating
* 5\. Patients with mental and neurological disorders who cannot cooperate with medical staff
* 6\. Patients with severe diabetes or poor glycemic control
* 7\. Patients cannot tolerate nutritional preparations
* 8\. Other circumstances that the researcher considers inappropriate to participate in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kun Wang, Doctor

Role: STUDY_CHAIR

Tianjin Medical University cancer Instituteand Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tianjin Medical University cancer Instituteand Hospital

Tianjin, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chunlei Li, Doctor

Role: CONTACT

18622370261

Kun Wang, Doctor

Role: CONTACT

23340123 ext. 1155

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kun Wang

Role: primary

23340123 ext. 1155

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20191226

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.